conflict of interest€¦ · mortality, ivh, nec, pvl, surfactant, etc. ... former 28 week preemie...

12
Neonatal Heated High Flow Nasal Cannula: Just Say No or Go with the Flow? Rob DiBlasi RRT-NPS, FAARC Program Manager Research/QI, Respiratory Therapy Principle Investigator, Seattle Children’s Research Institute Conflict of Interest I have received research funds and/or speaker honoraria from the follow manufacturers: Vapotherm Neotech Draeger Medical Mallinckrodt Medical Aerogen Pharma Chiesi Pharma Objectives Learning objectives for this presentation: Review theoretic functional differences between Nasal CPAP and high flow nasal cannula (HFNC) Explore physiologic data comparing HFNC to other noninvasive strategies Discuss clinical data related to HFNC use in neonates Determine best practice for HFNC management and weaning Heated and Humidified High Flow Nasal Cannula (HFNC) CO 2 CO 2 + + + + + + + + + + + + + + + HFNC provides a monophasic oxygen flow heated and humidified (100% BTPS) “Open System” resulting in leaks Improves oxygenation: PaO2 (FiO2), humidity, PEEP Improves ventilation PaCO 2 , V T , RR and VE CO 2 rebreathing from anatomic deadspace Indicated therapeutic flow setting currently unknown

Upload: others

Post on 23-Mar-2021

0 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Conflict of Interest€¦ · mortality, IVH, NEC, PVL, surfactant, etc. ... Former 28 week preemie with severe BPD admitted for viral bronchiolitis • Receiving 7 L/min HFNC •

Neo

nata

l Hea

ted

Hig

h Fl

ow N

asal

C

annu

la: J

ust S

ay N

o or

Go

with

th

e Fl

ow?

Rob

DiB

lasi

RR

T-N

PS, F

AAR

C

Prog

ram

Man

ager

Res

earc

h/Q

I, R

espi

rato

ry T

hera

py

Prin

cipl

e In

vest

igat

or, S

eattl

e C

hild

ren’

s R

esea

rch

Inst

itute

Con

flict

of I

nter

est

I hav

e re

ceiv

ed re

sear

ch fu

nds a

nd/o

r spe

aker

ho

nora

ria fr

om th

e fo

llow

man

ufac

ture

rs:

•Va

poth

erm

Neo

tech

Drae

ger M

edic

al

•M

allin

ckro

dt M

edic

al

•Ae

roge

n Ph

arm

a •

Chie

si Ph

arm

a

Obj

ectiv

es

Lear

ning

obj

ectiv

es fo

r thi

s pre

sent

atio

n:

•Re

view

theo

retic

func

tiona

l diff

eren

ces b

etw

een

Nas

al C

PAP

and

high

flow

nas

al c

annu

la (H

FNC)

Expl

ore

phys

iolo

gic

data

com

parin

g HF

NC

to o

ther

no

ninv

asiv

e st

rate

gies

Disc

uss c

linic

al d

ata

rela

ted

to H

FNC

use

in

neon

ates

Dete

rmin

e be

st p

ract

ice

for H

FNC

man

agem

ent

and

wea

ning

Hea

ted

and

Hum

idifi

ed H

igh

Flow

Nas

al

Can

nula

(HFN

C)

CO

2

CO

2

+ +

+

+ + +

+ +

+

+ +

+ +

+ +

•H

FNC

pro

vide

s a

mon

opha

sic

oxyg

en fl

ow

•he

ated

and

hum

idifi

ed

(100

% B

TPS)

“Ope

n S

yste

m” r

esul

ting

in

leak

s •

Impr

oves

oxy

gena

tion:

↑PaO

2 (F

iO2)

, hum

idity

, PE

EP

•Im

prov

es v

entil

atio

n •↓P

aCO

2, ↑V

T , ↓

RR

and

VE

•↓

CO

2 reb

reat

hing

from

an

atom

ic d

eads

pace

Indi

cate

d th

erap

eutic

flow

se

tting

cur

rent

ly u

nkno

wn

Page 2: Conflict of Interest€¦ · mortality, IVH, NEC, PVL, surfactant, etc. ... Former 28 week preemie with severe BPD admitted for viral bronchiolitis • Receiving 7 L/min HFNC •

HFN

C In

terfa

ces

may

be

mor

e co

mfo

rtabl

e th

an N

-CPA

P

Pho

tos

Cou

rtesy

of R

ose

DeC

lerk

, Ver

mon

t Oxf

ord

and

Loui

se O

wen

G

ollg

her e

t al.,

Am

J R

esp.

and

Crit

. Car

e M

ed, 2

017

HFN

C In

terfa

ces

may

be

mor

e co

mfo

rtabl

e th

an N

-CPA

P

Pho

tos

Cou

rtesy

of R

ose

DeC

lerk

, Ver

mon

t Oxf

ord

and

Loui

se O

wen

Perc

eive

d lim

itatio

ns o

f HFN

C

•Pr

essu

re is

hig

hly

varia

ble

and

cann

ot b

e m

easu

red

or re

gula

ted

•Th

ere

are

no a

larm

s w

ith m

ost H

FNC

sys

tem

s

•D

iste

ndin

g ai

rway

pre

ssur

e ge

nera

ted

by H

FNC

m

ay le

ad to

lung

inju

ry (o

vere

xpan

sion

or

atel

ecta

sis)

and

con

tribu

te to

the

deve

lopm

ent o

f BP

D in

infa

nts

•In

abilit

y to

sel

ect p

rope

rly s

ized

pro

ngs

coul

d in

crea

se ri

sk fo

r VIL

I and

gas

tric

insu

fflat

ion

Page 3: Conflict of Interest€¦ · mortality, IVH, NEC, PVL, surfactant, etc. ... Former 28 week preemie with severe BPD admitted for viral bronchiolitis • Receiving 7 L/min HFNC •

Airw

ay In

jury

with

Nas

al C

PAP

•C

PAP

use

may

: •

Incr

ease

the

risk

for t

issu

e ne

cros

is,

nasa

l ste

nosi

s, d

efor

mity

, and

PnT

x •

Incr

ease

d ne

ed fo

r sed

atio

n •

Inte

rface

may

impa

ct b

ondi

ng, s

uck

feed

ing,

and

pos

ition

ing

•R

epor

ted

adva

ntag

es o

f HFN

C o

ver

CPA

P:

•R

educ

ed ra

tes

of n

asal

trau

ma

Red

uced

infa

nt p

ain

scor

es a

nd

stre

ss

•Pr

efer

red

by p

aren

ts a

nd n

ursi

ng

staf

f •

Less

PnT

x

Phys

ic o

f Gas

Flo

w: N

CPA

P

DiB

lasi

,. R

esp.

Car

e Jo

urna

l, 20

16

Hig

h Fl

ow N

asal

Can

nula

Fl

ow R

ate>

2 L

/min

; mon

opha

sic

flow

CO

2

CO

2

+ +

+

+ + +

+ +

+

+ +

+ +

+ +

Pho

to c

ourte

sy o

f Tom

Mill

er P

hD

Eve

rybo

dy S

eem

s to

Be

Goi

ng W

ith th

e Fl

ow…

.

Page 4: Conflict of Interest€¦ · mortality, IVH, NEC, PVL, surfactant, etc. ... Former 28 week preemie with severe BPD admitted for viral bronchiolitis • Receiving 7 L/min HFNC •

It is

Bei

ng U

sed

to T

reat

a

Num

ber o

f Mal

adie

s…

Is it

pos

sibl

e th

at it

is b

eing

app

lied

whe

n it

is n

ot

alw

ays

nece

ssar

ily in

dica

ted?

No

one

Know

s W

hat t

he F

low

Sho

uld

Be

Set

At…

024681012

Feb-12

Apr-12

Jun-12

Aug-12

Oct-12

Dec-12

Feb-13

Apr-13

Jun-13

Aug-13

Oct-13

Dec-13

Feb-14

Apr-14

Jun-14

Aug-14

Oct-14

Dec-14

Feb-15

Apr-15

% of All Pt Days with HFNC in Use

THE

QU

ESTI

ON

: Ove

rutil

izat

ion

of H

FNC

?

•W

hat l

evel

of s

uppo

rt is

pro

vide

d w

ith H

FNC

? •

Are

ther

e ph

ysio

logi

c be

nefit

s w

ith H

FNC

? •

A m

anag

emen

t pro

toco

l in

the

US

is

none

xist

ent

(Infa

nt th

roug

h A

dult)

Page 5: Conflict of Interest€¦ · mortality, IVH, NEC, PVL, surfactant, etc. ... Former 28 week preemie with severe BPD admitted for viral bronchiolitis • Receiving 7 L/min HFNC •

Tran

slat

iona

l Res

earc

h Q

uest

ions

•D

oes

HFN

C p

rovi

de p

ress

ure

sim

ilar t

o C

PAP?

Doe

s H

FNC

redu

ced

exha

led

CO

2re

-bre

athi

ng fr

om th

e an

atom

ic d

eads

pace

? •

Are

ther

e di

ffere

nces

in th

e le

vel o

f CO

2w

asho

ut re

late

d to

di

ffere

nt p

atie

nt s

izes

? •

Wha

t hap

pens

to p

ress

ures

and

CO

2 with

mou

th

open

/clo

sed?

Can

thes

e ef

fect

s be

stu

died

in a

ben

ch m

odel

or h

uman

s?

•C

an H

FNC

use

affe

ct o

utco

mes

in o

ur p

atie

nt p

opul

atio

n th

at a

re d

iffer

ent f

rom

oth

er n

onin

vasi

ve fo

rms

of s

uppo

rt?

Nie

lsen

et a

l., In

Pre

ss R

espi

rato

ry C

are

Jour

nal,

2017

End-

Expi

rato

ry P

ress

ures

Niel

sen

et a

l., In

Pre

ss R

espi

rato

ry C

are

Jour

nal,

2017

End

expi

rato

ry p

ress

ure

with

HFN

C

Iyer

et a

l., R

espi

rato

ry C

are

Jour

nal,

2016

Page 6: Conflict of Interest€¦ · mortality, IVH, NEC, PVL, surfactant, etc. ... Former 28 week preemie with severe BPD admitted for viral bronchiolitis • Receiving 7 L/min HFNC •

Flow

Effe

cts:

End

-Tid

al C

O2

(alv

eola

r ve

ntila

tion)

2L:2

6.3±

2.7

2L: 3

5.4±

1.7

2L: 5

.3±1

.3

2 L:

10.

4±1.

6

4 L:

7.2

±0.9

4

L: 1

9.1±

0.7

6 L:

7.6

±2.1

Flow

Effe

cts I

nsp.

CO

2 (d

eads

pace

)

Pre-

term

: Vap

othe

rm 8

L/m

in

Term

: Vap

othe

rm 8

L/m

in

Adul

t: Va

poth

erm

40

L/m

in

"Whe

re th

ere

is n

o st

anda

rd, t

here

can

be n

o im

prov

emen

t"

-Tai

ichi

Ohn

o

Prot

ocol

Dev

elop

men

t

Age

Gro

upD

efin

ition

of H

FNC

*

Acut

e C

are

Min

imum

H

FNC

Flo

w R

ate

(bro

nchi

oliti

s pa

thw

ay)

Acut

e C

are

Max

imum

H

FNC

Flo

w R

ate

IC

U M

axim

um H

FNC

Flo

w R

ates

Flow

Rat

e (L

/min

)

Estim

ated

PE

EP

(cm

H2O

)

HFN

C

min

imum

(L

/min

)

Estim

ated

PEEP

(cm

H20

)

HFN

C

max

imum

(L

/min

)

Estim

ated

PE

EP

(cm

H2O

)

HFN

C

max

imum

(L

/min

)

Estim

ated

PE

EP (c

m H

2O)

0-90

d3

2 3

2 4

3 8

10

91d-

6mo

4 <1

4<1

6 2

106

>6m

o-1y

r 5

<15

<18

2 12

-20

4-10

>1 y

r-2y

r 6

<25

<110

3 15

-20

6-10

>2yr

-8yr

6

<16

<112

2 15

-20

4-6

>8yr

s8

<18

<115

2 15

-30

4-12

PEEP

val

ues

are

estim

ated

at e

ach

HFN

C s

ettin

gs u

sing

a s

pont

aneo

usly

bre

athi

ng lu

ng m

odel

and

3D

ana

tom

ic a

irway

with

Vap

othe

rm

devi

ce.

*

HFN

C d

efin

ition

bas

ed o

n es

timat

ed in

spira

tory

flow

for a

vera

ge w

eigh

t in

term

infa

nt th

roug

h ad

oles

cent

pat

ient

s; p

atie

nts

who

are

no

t on

the

bron

chio

litis

pat

hway

and

are

rece

ivin

g flo

w b

elow

that

def

ined

as

HFN

C fo

r age

may

be

cand

idat

es fo

r wea

ning

/ di

scon

tinua

tion

and

shou

ld b

e di

scus

sed

with

med

ical

team

; pat

ient

s re

quiri

ng o

xyge

n af

ter H

FNC

sho

uld

be s

uppo

rted

with

a N

C a

ttach

ed to

an

oxyg

en fl

ow

met

er (w

ithou

t ble

nder

) bef

ore

acut

e ca

re tr

ansf

er.

Page 7: Conflict of Interest€¦ · mortality, IVH, NEC, PVL, surfactant, etc. ... Former 28 week preemie with severe BPD admitted for viral bronchiolitis • Receiving 7 L/min HFNC •

Is C

O2 r

espo

nse

betw

een

HFN

C, N

CPAP

, and

NIV

Di

ffere

nt?

Muk

erji

et a

l. J P

erin

atol

. 201

5

↓28

%

↓44

%

↓15

%

↓35

%

Clin

ical

Out

com

es: C

ompa

ring

HFN

C to

NIV

•H

FNC

doe

sno

t pro

vide

insp

irato

ry p

ress

ure

but

CO

2 pur

ging

dur

ing

inha

latio

n an

d ex

hala

tion

may

pr

ovid

e a

sim

ilar v

entil

atio

n ef

fect

as

NIV

HH

HFN

C m

aybe

as

effe

ctiv

e as

NIP

PV in

pr

even

ting

endo

trach

eal v

entil

atio

n in

the

prim

ary

treat

men

t of R

DS

in p

rem

atur

e in

fant

s

•N

eona

tes

Kug

lem

an,P

eds

Pul

m, 2

016;

Lav

azar

ri 20

16, J

amaP

edia

trics

•Ad

ults

NiY

N, C

hest

. 201

7, N

agat

a K

, Res

pira

tory

Car

e 20

15

NO

doc

umen

ted

airw

ay In

jury

or p

neum

otho

rax

-.20 .2.4.6.81

1.2

NC

PAP-

NIM

V PE

R P

T D

AY

HH

FNC

PER

PT

DAY

IN

VASI

VE V

ENTS

PER

PT

DAY

2016

2015

2014

2013

2012

↓57%

↓36%

↑58%

2016

2015

2014

2013

2012

2016

2015

2014

2013

2012

HFN

C U

se a

t SC

H: A

Sna

p Sh

ot fr

om th

e N

ICU

% c

hang

e ba

sed

on m

ean

valu

es

Total Days of Therapy/Total Patient Days

Page 8: Conflict of Interest€¦ · mortality, IVH, NEC, PVL, surfactant, etc. ... Former 28 week preemie with severe BPD admitted for viral bronchiolitis • Receiving 7 L/min HFNC •

Shor

t-ter

m p

hysi

olog

ic o

utco

mes

: WO

B

Neu

th e

t al.,

Ped

s P

ulm

46:

67-7

4 (2

011)

Shor

t-ter

m P

hysi

olog

ic S

tudi

es: r

ecru

itmen

t

Clin

ical

Que

stio

ns

•C

an H

FNC

be

used

saf

ely

and

effe

ctiv

ely

as a

n al

tern

ativ

e to

N-C

PAP

in te

rm a

nd p

re-te

rm

infa

nts

as a

n in

itial

form

of s

uppo

rt or

follo

win

g ex

tuba

tion?

Shor

t-ter

m p

ulm

onar

y ph

ysio

logi

c ou

tcom

es (W

OB,

ga

s ex

chan

ge, A

OP,

and

lung

recr

uitm

ent)

•M

orbi

dity

/mor

talit

y (D

eath

, BPD

, oth

er c

ompl

icat

ions

) •

Nas

al a

irway

inju

ry

•Pn

eum

otho

rax

HFN

C in

Pre

mat

ure

Infa

nts

Follo

win

g Ex

tuba

tion

•Fo

llow

ing

extu

batio

n (6

stu

dies

,n=9

34),

no d

iffer

ence

s be

twee

n H

FNC

and

CPA

P:

•de

ath

or C

LD

•ra

te o

f tre

atm

ent f

ailu

re o

r rei

ntub

atio

n

•In

fant

s ra

ndom

ized

to H

FNC

had

low

er n

asal

trau

ma

and

pneu

mot

hora

x

•Su

bgro

up a

naly

sis

foun

d no

diff

eren

ce in

the

rate

of t

he p

rimar

y ou

tcom

es b

etw

een

HFN

C a

nd C

PAP

in p

rete

rm in

fant

s in

diff

eren

t ge

stat

iona

l age

sub

grou

ps, s

mal

l num

ber i

nfan

ts <

1200

gra

ms

•Fo

r inf

ants

wea

ning

from

non

-inva

sive

resp

irato

ry s

uppo

rt (C

PAP)

, tw

o st

udie

s (n

=149

) fou

nd th

at p

rete

rm in

fant

s ra

ndom

ized

to H

FNC

ha

d a

redu

ced

dura

tion

of h

ospi

taliz

atio

n co

mpa

red

with

infa

nts

who

re

mai

ned

on C

PAP

Page 9: Conflict of Interest€¦ · mortality, IVH, NEC, PVL, surfactant, etc. ... Former 28 week preemie with severe BPD admitted for viral bronchiolitis • Receiving 7 L/min HFNC •

•R

CT

- HFN

C n

onin

ferio

r to

CPA

P as

prim

ary

resp

irato

ry

supp

ort f

or p

rete

rm in

fant

s (g

esta

tiona

l age

, ≥28

wee

ks 0

da

ys) w

ith e

arly

RD

S•

HFN

C g

roup

rece

ived

an

initi

al g

as fl

ow o

f 6 to

8 L

/min

from

ei

ther

the

Opt

iflow

Jun

ior (

F&P

Hea

lthca

re) o

r Pre

cisi

on

Flow

(Vap

othe

rm)d

evic

e w

ith c

ross

over

to N

-CPA

P (9

4% v

s 6%

) •

Nas

al C

PAP

grou

p re

ceiv

ed 6

-8 c

mH

2O u

sing

thre

e di

ffere

nt

kind

s of

N-C

PAP

Rob

erts

et a

l., N

EJM

, 201

6

The

“HIP

STE

R T

rial”

Out

com

es

•St

udy

stop

ped

afte

r tw

o ye

ars;

HFN

C=2

78 a

nd C

PAP=

286

•Tr

eatm

ent f

ailu

re (F

iO2

>0.4

0) w

ithin

72

hour

s af

ter r

ando

miz

atio

n w

as g

reat

er (2

5.5%

) in

the

HFN

C th

an N

-CPA

P gr

oup

(13.

3 vs

25

.5%

; P<0

.001

) •

Leng

th o

f sup

port

and

oxyg

en re

quire

men

t gre

ater

in H

FNC

gro

up

•N

o di

ffere

nce

in in

tuba

tion

rate

s at

72

hour

s (1

5.5

vs 1

1.5)

, BPD

, m

orta

lity,

IVH

, NEC

, PVL

, sur

fact

ant,

etc.

Urg

ent n

eed

for i

ntub

atio

n oc

curre

d m

ore

frequ

ently

in th

e C

PAP

grou

p th

an H

FNC

gro

up (1

8.4%

vs.

5.6

%, P

= 0

.03)

Nas

al tr

aum

a (8

.3 v

s 18

.5%

; P<0

.001

) and

pne

umot

hora

x an

d ai

r-le

ak lo

wer

(0 v

s 6%

; P<0

.02)

dur

ing

HFN

C th

an N

-CPA

P

Rob

erts

et a

l., N

EJM

, 201

6

HFN

C U

se In

BPD

•Pr

actic

es a

re d

ispa

rate

nat

iona

lly a

nd s

ome

do n

ot u

se

HFN

C b

ecau

se th

ey a

re n

ot a

ble

to g

o ho

me

with

it

•W

eani

ng a

t SC

H is

clin

ical

ly-b

ased

: •

Trac

heom

alac

ia o

r oth

er a

irway

ano

mal

ies

(obs

truct

ion)

Gas

Exc

hang

e: s

erum

CO

2an

d H

CO

3-

•R

R a

nd W

OB

•Ju

dici

ous

redu

ctio

ns in

flow

(~0.

5 to

1 L

/min

/wk)

•W

eani

ng H

FNC

coi

ncid

es w

ith s

tero

id w

ean

HFN

C U

se In

BPD

•Fo

rmer

28

wee

k pr

eem

ie

with

sev

ere

BPD

adm

itted

fo

r vira

l bro

nchi

oliti

s •

Rec

eivi

ng 7

L/m

in H

FNC

Enro

lled

in H

FNC

stu

dy

•N

o Ai

rway

Ano

mal

ies

or

TBM

Page 10: Conflict of Interest€¦ · mortality, IVH, NEC, PVL, surfactant, etc. ... Former 28 week preemie with severe BPD admitted for viral bronchiolitis • Receiving 7 L/min HFNC •

Phys

iolo

gic

Effe

cts

of H

FNC

in B

PD

DiB

lasi

et a

l.,U

npub

lishe

d D

ata

Car

diac

Pat

ient

s: A

sen

sitiv

e Pa

tient

Pop

ulat

ion

Shi

oji e

t al.,

Jou

rnal

of I

nten

sive

Car

e 20

17

Post

-ext

ubat

ion

HFN

C vs

NIM

V (in

fant

s)

Age

2 m

onth

s (0.

5, 4

) M

ale

(%)

22 (5

2%)

Ethn

icity

Hisp

anic

26

(61%

)

W

hite

14

(33%

)

O

ther

3

(6%

) W

eigh

t (ra

nge)

3.

6 kg

(2.2

-9.6

) Re

ason

for i

ntub

atio

n

Cong

enita

l Hea

rt D

iseas

e Su

rger

y (%

) 30

(71%

)

Re

spira

tory

Fai

lure

(%)

10 (2

3%)

Leng

th o

f Mec

hani

cal V

entil

atio

n (r

ange

) 7

days

(2-3

0)

Leng

th o

f Non

inva

sive

Vent

ilatio

n (r

ange

) 1

(0.2

-29

days

)

Ran

dom

ized

cro

ss o

ver t

rial a

fter e

xtub

atio

n (n

=42)

Kam

erka

r et a

l., J

Pedi

atr 2

017

Page 11: Conflict of Interest€¦ · mortality, IVH, NEC, PVL, surfactant, etc. ... Former 28 week preemie with severe BPD admitted for viral bronchiolitis • Receiving 7 L/min HFNC •

No

diffe

renc

e in

effo

rt o

f bre

athi

ng b

etw

een

HFN

C an

d N

IMV,

rega

rdle

ss o

f flo

w ra

te

or in

spira

tory

pre

ssur

e (K

rusk

al-W

allis

AN

OVA

P = .1

5). Ka

mer

kar e

t al.,

J Pe

diat

r 201

7 N

ewbo

rn in

fant

s -6

mon

ths (

70%

with

CHD

)

HFN

C U

se In

Bro

nchi

oliti

s

•C

ochr

ane

Met

a-an

alys

is

(201

4):

•Th

ere

is in

suffi

cien

t evi

denc

e to

det

erm

ine

the

effe

ctiv

enes

s of

HFN

C th

erap

y fo

r tre

atin

g in

fant

s w

ith b

ronc

hiol

itis

•“A

bsen

ce o

f evi

denc

e m

ay n

ot

be e

vide

nce

of a

bsen

ce”

•Sh

ort-t

erm

phy

siol

ogic

stu

dies

ha

ve s

how

n im

prov

ed g

as

exch

ange

and

redu

ced

WO

B

HFN

C U

tiliz

atio

n in

Pat

ient

s w

ith B

ronc

hiol

itis

HFN

C M

anag

emen

t Gui

delin

es

Page 12: Conflict of Interest€¦ · mortality, IVH, NEC, PVL, surfactant, etc. ... Former 28 week preemie with severe BPD admitted for viral bronchiolitis • Receiving 7 L/min HFNC •

Jour

nal o

f Per

inat

olog

y 20

17

"Whe

re th

ere

is n

o st

anda

rd, t

here

can

be n

o im

prov

emen

t"

-Tai

ichi

Ohn

o

Prot

ocol

Dev

elop

men

t

Age

Gro

upD

efin

ition

of H

FNC

*

Acut

e C

are

Min

imum

H

FNC

Flo

w R

ate

(bro

nchi

oliti

s pa

thw

ay)

Acut

e C

are

Max

imum

H

FNC

Flo

w R

ate

IC

U M

axim

um H

FNC

Flo

w R

ates

Flow

Rat

e (L

/min

)

Estim

ated

PE

EP

(cm

H2O

)

HFN

C

min

imum

(L

/min

)

Estim

ated

PEEP

(cm

H20

)

HFN

C

max

imum

(L

/min

)

Estim

ated

PE

EP

(cm

H2O

)

HFN

C

max

imum

(L

/min

)

Estim

ated

PE

EP (c

m H

2O)

0-90

d3

2 3

2 4

3 8

10

91d-

6mo

4 <1

4<1

6 2

106

>6m

o-1y

r 5

<15

<18

2 12

-20

4-10

>1 y

r-2y

r 6

<25

<110

3 15

-20

6-10

>2yr

-8yr

6

<16

<112

2 15

-20

4-6

>8yr

s8

<18

<115

2 15

-30

4-12

PEEP

val

ues

are

estim

ated

at e

ach

HFN

C s

ettin

gs u

sing

a s

pont

aneo

usly

bre

athi

ng lu

ng m

odel

and

3D

ana

tom

ic a

irway

with

Vap

othe

rm

devi

ce.

*

HFN

C d

efin

ition

bas

ed o

n es

timat

ed in

spira

tory

flow

for a

vera

ge w

eigh

t in

term

infa

nt th

roug

h ad

oles

cent

pat

ient

s; p

atie

nts

who

are

no

t on

the

bron

chio

litis

pat

hway

and

are

rece

ivin

g flo

w b

elow

that

def

ined

as

HFN

C fo

r age

may

be

cand

idat

es fo

r wea

ning

/ di

scon

tinua

tion

and

shou

ld b

e di

scus

sed

with

med

ical

team

; pat

ient

s re

quiri

ng o

xyge

n af

ter H

FNC

sho

uld

be s

uppo

rted

with

a N

C a

ttach

ed to

an

oxyg

en fl

ow

met

er (w

ithou

t ble

nder

) bef

ore

acut

e ca

re tr

ansf

er.

0%1%2%3%4%5%6%7%8%9%10%

11%

12%

13%

14%

Jan-13Feb-13Mar-13Apr-13

May-13Jun-13Jul-13

Aug-13Sep-13Oct-13Nov-13Dec-13Jan-14Feb-14Mar-14Apr-14

May-14Jun-14Jul-14

Aug-14Sep-14Oct-14Nov-14Dec-14Jan-15Feb-15Mar-15Apr-15

May-15Jun-15Jul-15

Aug-15Sep-15Oct-15Nov-15Dec-15Jan-16Feb-16Mar-16Apr-16

May-16Jun-16Jul-16

Aug-16Sep-16Oct-16Nov-16Dec-16Jan-17Feb-17

PERCENT OF PT DAYS ON HFNC

PERC

ENT

OF

PT D

AYS

ON

HFN

C Is

it a

ll ho

t air?